μαθιψΰφθν θας ® 500 ξ"β
|
ων δϊψετδ αΰπβμιϊ: Levetiracetam Teva ® 500 Mg.
ξητωιν ϊψετδ ΰηψϊ? λπρε μΰιπγχρ δϊψετεϊ »
|
|
 αρμ δαψιΰεϊ
φεψϊ ξϊο
PER OS
ξιπεο
Tablets
ωιξεω αϊψετδ
- Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - Levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.- Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patient from 16 years of age with newly diagnosed epilepsy.- Levetiracetam is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.
ξρτψ ψιωεν
141 44 31957 00
ιφψο
Teva Pharmaceutical Industries Ltd
ϊεχσ ψιωιεο μϊψετδ
08/2014 - 08/2024
ηεξψ τςιμ
|
ψιλεζ / λξεϊ αιηιγϊ ξιπεο
|
Levetiracetam |
500 MG |
ΰψιζδ
|
λξεϊ αΰψιζδ
|
ηιι ξγσ
|
ϊψετϊ ξψων
|
Blister pvdc/aluminium |
30 x TABLETS |
ηεγωιν 36 |
λο |
Blister pvdc/aluminium |
60 x TABLETS |
ηεγωιν 36 |
λο |
|
|
|